Page 1 of 1
Siponimod reduces risk of disability progression by 21%
Posted: Tue May 09, 2017 12:15 am
by MSUK
Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent, over a three month period...Read more -
http://www.ms-uk.org/siponimod-reduces- ... ent-090517
Re: Siponimod reduces risk of disability progression by 21%
Posted: Sat Apr 27, 2019 2:53 pm
by NHE
MSUK wrote: ↑Tue May 09, 2017 12:15 am
Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent.
That sounds good. However, it's a relative percentage reduction. The actual data plot doesn't look that impressive.
Re: Siponimod reduces risk of disability progression by 21%
Posted: Sat Apr 27, 2019 4:27 pm
by Zyklon
I agree with NHE. Not much improvement and lots of possible side effects.